Clinical application value of blood creatinine/cystatin C ratio in diagnos-ing skeletal muscle mass reduction in patients with fatty liver disease
Objective To explore the clinical application value of the blood creatinine to cystatin C ratio(CCR)in diagnosing skeletal muscle mass reduction in patients with non-alcoholic fatty liver disease(NAFLD).Methods A total of 388 NAFLD patients hospitalized at Karamay Central Hospital from October 2023 to March 2024 were selected and divided into a training set(310 cases)and a validation set(78 cases)at an 8∶2 ratio.Clinical data and body composition data were collected for both groups.Multivariate logistic regression analysis was performed to identify risk factors for skeletal muscle mass reduction and to construct a nomogram model.The model's predictive performance was evaluated using ROC curves and Hosmer-Lem show calibration curves.Results Among the 388 patients surveyed,187 exhibited skeletal muscle mass reduction.Significant differences were observed between the skeletal muscle mass reduction group and the non-reduction group in terms of BMI,CCR,and hs-CRP(P＜0.05).Restrictive cubic splines indicated an"L"shaped relationship between CCR and skeletal mus-cle reduction,while hs-CRP demonstrated a"J"shaped relationship(both P＜0.001).Logistic regression analysis revealed that a higher CCR was a protective factor for skeletal muscle mass(OR=8.579,95％CI:3.459-13.905).The AUC of the ROC curve for the nomogram prediction model was 0.89(95％CI:0.856-0.951).The model exhibited good fit,and the calibration plot demonstrated a strong alignment with the standard curve.Conclusion BMI,CCR,and hs-CRP are independent risk fac-tors for skeletal muscle mass reduction in NAFLD patients.The established nomogram model can provide individualized risk predictions and assist in the early identification of high-risk populations.
Non-alcoholic fatty liver diseaseCreatinine/Cystatin C ratioHigh-sensitivity C-reactive proteinSkeletal muscle mass reductionNomogram prediction model
NETL
NSTL
万方数据
